The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells.

The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells.
复制标题

DOI:
10.1084/jem.20011838
复制
发表时间:
2002-08-05
期刊:
The Journal of experimental medicine
影响因子:
--
通讯作者:
Goulmy E
Goulmy E
中科院分区:
其他
文献类型:
--
作者:
Klein CA;Wilke M;Pool J;Vermeulen C;Blokland E;Burghart E;Krostina S;Wendler N;Passlick B;Riethmüeller G;Goulmy E

文献摘要

参考文献

被引文献

相似文献

同种异体干细胞移植(SCT)可以诱导血液系统恶性肿瘤和实体肿瘤患者的移植物抗肿瘤反应。人类组织相容性白细胞抗原(HLA)相同的SCT后的移植物抗肿瘤反应是由特异性多态次要组织相容性抗原(mHags)的同种免疫供体T细胞介导的。其中,mHag HA-1被发现局限于造血系统。在这里,我们报道了HA-1核糖核酸在微解剖癌组织和从各种上皮肿瘤患者分离的单播散性肿瘤细胞中的表达。HA-1肽是分子定义的,因为它与HLA-A2在癌细胞细胞系的细胞膜上形成免疫原性肽配体。ha -1特异性细胞毒性T细胞在体外可裂解上皮肿瘤细胞系,而正常上皮细胞不被识别。因此,HA-1特异性免疫疗法联合hla -相同的同种异体SCT现在可能对HA-1+癌患者是可行的。
Allogeneic stem cell transplantation (SCT) can induce curative graft-versus-tumor reactions in patients with hematological malignancies and solid tumors. The graft-versus-tumor reaction after human histocompatibility leukocyte antigen (HLA)-identical SCT is mediated by alloimmune donor T cells specific for polymorphic minor histocompatibility antigens (mHags). Among these, the mHag HA-1 was found to be restricted to the hematopoietic system. Here, we report on the HA-1 ribonucleic acid expression by microdissected carcinoma tissues and by single disseminated tumor cells isolated from patients with various epithelial tumors. The HA-1 peptide is molecularly defined, as it forms an immunogenic peptide ligand with HLA-A2 on the cell membrane of carcinoma cell lines. HA-1–specific cytotoxic T cells lyse epithelial tumor cell lines in vitro, whereas normal epithelial cells are not recognized. Thus, HA-1–specific immunotherapy combined with HLA-identical allogeneic SCT may now be feasible for patients with HA-1+ carcinomas.
DOI: 10.1007/bf00185109
发表时间: 1992-02-01
期刊: IMMUNOGENETICS
影响因子: 3.2
作者:
VANELS, CACM;DAMARO, J;GOULMY, E
通讯作者: GOULMY, E
DOI: 10.1182/blood.v88.4.1501.bloodjournal8841501
发表时间: 1996-08-15
期刊: BLOOD
影响因子: 20.3
作者:
Eibl, B;Schwaighofer, H;Niederwieser, D
通讯作者: Niederwieser, D
DOI: 10.1016/s1074-7613(95)80053-0
发表时间: 1995-02-01
期刊: IMMUNITY
影响因子: 32.4
作者:
BOEL, P;WILDMANN, C;VANDERBRUGGEN, P
通讯作者: VANDERBRUGGEN, P
DOI: 10.1182/blood.v93.7.2336.407k26_2336_2341
发表时间: 1999-04-01
期刊: BLOOD
影响因子: 20.3
作者:
Mutis, T;Verdijk, R;Goulmy, E
通讯作者: Goulmy, E
DOI: 10.1084/jem.174.1.27
发表时间: 1991-07-01
影响因子: 15.3
作者:
FALKENBURG, JHF;GOSELINK, HM;GOULMY, E
通讯作者: GOULMY, E